Potential Drug Target Or Biomarker for Various Diseases: Functions of Trav26-1

Target Name: TRAV26-1

NCBI ID: G28657

TRAV26-1

Other Name(s): TCRAV26S1 | TRAV261 | TCRAV4S2 | T cell receptor alpha variable 26-1

Potential Drug Target Or Biomarker for Various Diseases: Functions of Trav26-1

Trav26-1 (TCRAV26S1) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and pancreas. It is a member of the Tetraspanin family of proteins, which are known for their involvement in various cellular processes, including cell signaling, cytoskeletal organization, and intracellular transport.

One of the unique features of Trav26-1 is its ability to interact with various signaling molecules, including T-cell kinases, G-protein-coupled receptors (GPCRs), and microtubules. This interaction with these molecules has led to the hypothesis that Trav26-1 may be a drug target or biomarker for various diseases.

In addition to its potential as a drug target, Trav26-1 has also been suggested as a potential biomarker for several diseases. For example, Trav26-1 has been shown to be highly expressed in the pancreatic cancer, and may be a useful biomarker for this disease. Additionally, Trav26-1 has been shown to be involved in the regulation of inflammation and fibrosis, and may be a useful biomarker for diseases that involve these processes, such as rheumatoid arthritis (RA) and chronic obstructive pulmonary disease (COPD).

The specific functions of Trav26-1 are not yet fully understood, but its potential role in disease suggests that it may be an important target for researchers to investigate. Further studies are needed to determine the exact mechanisms by which Trav26-1 interacts with these signaling molecules and to explore its potential as a drug target or biomarker.

Protein Name: T Cell Receptor Alpha Variable 26-1

Functions: V region of the variable domain of T cell receptor (TR) alpha chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRAV26-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAV26-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets